Stay updated with breaking news from A Contract Testing Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...
PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the laun...
/PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
TESSA™ technology provides a scalable process for manufacturing gene therapies, accelerating the production of large quantities of therapeutic DNA required to treat patients in need.